FollowMyHealth Patient Portal

David Michael Holtzman, MD

Andrew B. and Gretchen P. Jones Professor of Neurology
Charlotte and Paul Hagemann Professor of Neurology
Chairman, Department of Neurology
Professor, Molecular Biology and Pharmacology
Neurologist-in-Chief, Barnes-Jewish Hospital

Specialty Areas

Neurology - Adult
Memory Disorders and Diagnosis
Alzheimer's Disease
Dementia

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Neurology, molecular biology, pharmacology, nervous system, Alzheimer's disease, memory, brain research, cerebral blood flow, metabolism, neuroscience, lipid research, neuron, mental retardation, Down's syndrome, neonatal hypoxic-ischemia, brain disorders, spinal fluid.

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Memory Diagnostic Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 286-1967
Fax: (314) 286-1985
Email: holtzman@neuro.wustl.edu

Education

Education

Residency: Neurology, University of California, San Francisco, California 1989
Medical Degree: Northwestern University, Chicago, Illinois 1985
BS: Science in Medical Education, Northwestern University, Chicago, Illinois 1983

Publication & Research

Publication & Research

Correction: AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.
Ising C, Gallardo G, Leyns CEG, Wong CH, Jiang H, Stewart F, Koscal LJ, Roh J, Robinson GO, Serrano JR, Holtzman DM
J Exp Med. 2017 May 23; pii: jem.2016212505192017c. doi: 10.1084/jem.2016212505192017c.

PMID:
    28536241
    [PubMed - as supplied by publisher]
Related citations


Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease.
Schindler SE, Jasielec MS, Weng H, Hassenstab JJ, Grober E, McCue LM, Morris JC, Holtzman DM, Xiong C, Fagan AM
Neurobiol Aging. 2017 Aug; 5625-32. doi: 10.1016/j.neurobiolaging.2017.04.004.

PMID:
    28482211
    [PubMed - in process]
Related citations


Diurnal oscillation of CSF Aβ and other AD biomarkers.
Lucey BP, Fagan AM, Holtzman DM, Morris JC, Bateman RJ
Mol Neurodegener. 2017 May 8; 12(1)36. doi: 10.1186/s13024-017-0161-4.

PMID:
    28478762
    [PubMed - in process]
Related citations


Neuropsychiatric Symptoms and Alzheimer's Disease Biomarkers Predict Driving Decline: Brief Report.
Babulal GM, Stout SH, Head D, Holtzman DM, Fagan AM, Morris JC, Roe CM
J Alzheimers Dis. 2017; 58(3)675-680. doi: 10.3233/JAD-170067.

PMID:
    28453487
    [PubMed - in process]
Related citations


Preclinical Alzheimer's disease and longitudinal driving decline.
Roe CM, Babulal GM, Head DM, Stout SH, Vernon EK, Ghoshal N, Garland B, Barco PP, Williams MM, Johnson A, Fierberg R, Fague MS, Xiong C, Mormino E, Grant EA, Holtzman DM, Benzinger TLS, Fagan AM, Ott BR, Carr DB, Morris JC
Alzheimers Dement (N Y). 2017 Jan; 3(1)74-82. doi: 10.1016/j.trci.2016.11.006.

PMID:
    28435853
    [PubMed - in process]
Related citations


Elucidating the Role of TREM2 in Alzheimer's Disease.
Ulrich JD, Ulland TK, Colonna M, Holtzman DM
Neuron. 2017 Apr 19; 94(2)237-248. doi: 10.1016/j.neuron.2017.02.042.

PMID:
    28426958
    [PubMed - in process]
Related citations


Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy.
Yanamandra K, Patel TK, Jiang H, Schindler S, Ulrich JD, Boxer AL, Miller BL, Kerwin DR, Gallardo G, Stewart F, Finn MB, Cairns NJ, Verghese PB, Fogelman I, West T, Braunstein J, Robinson G, Keyser J, Roh J, Knapik SS, Hu Y, Holtzman DM
Sci Transl Med. 2017 Apr 19; 9(386)pii: eaal2029. doi: 10.1126/scitranslmed.aal2029.

PMID:
    28424326
    [PubMed - in process]
Related citations


AAV-mediated expression of anti-tau scFvs decreases tau accumulation in a mouse model of tauopathy.
Ising C, Gallardo G, Leyns CEG, Wong CH, Stewart F, Koscal LJ, Roh J, Robinson GO, Remolina Serrano J, Holtzman DM
J Exp Med. 2017 May 1; 214(5)1227-1238. doi: 10.1084/jem.20162125.

PMID:
    28416651
    [PubMed - in process]
Related citations


Altered sleep and EEG power in the P301S Tau transgenic mouse model.
Holth JK, Mahan TE, Robinson GO, Rocha A, Holtzman DM
Ann Clin Transl Neurol. 2017 Mar; 4(3)180-190. doi: 10.1002/acn3.390.

PMID:
    28275652
    [PubMed]
Related citations


Astrocytic LRP1 Mediates Brain Aβ Clearance and Impacts Amyloid Deposition.
Liu CC, Hu J, Zhao N, Wang J, Wang N, Cirrito JR, Kanekiyo T, Holtzman DM, Bu G
J Neurosci. 2017 Apr 12; 37(15)4023-4031. doi: 10.1523/JNEUROSCI.3442-16.2017.

PMID:
    28275161
    [PubMed - indexed for MEDLINE]
Related citations


Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.
Deming Y, Li Z, Kapoor M, Harari O, Del-Aguila JL, Black K, Carrell D, Cai Y, Fernandez MV, Budde J, Ma S, Saef B, Howells B, Huang KL, Bertelsen S, Fagan AM, Holtzman DM, Morris JC, Kim S, Saykin AJ, De Jager PL, Albert M, Moghekar A, O'Brien R, Riemenschneider M, Petersen RC, Blennow K, Zetterberg H, Minthon L, Van Deerlin VM, Lee VM, Shaw LM, Trojanowski JQ, Schellenberg G, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Peskind ER, Li G, Di Narzo AF, Alzheimer’s Disease Neuroimaging Initiative (ADNI)., Alzheimer Disease Genetic Consortium (ADGC)., Kauwe JS, Goate AM, Cruchaga C
Acta Neuropathol. 2017 May; 133(5)839-856. doi: 10.1007/s00401-017-1685-y.

PMID:
    28247064
    [PubMed - indexed for MEDLINE]
Related citations


Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-β and other amyloidogenic proteins.
Huynh TV, Davis AA, Ulrich JD, Holtzman DM
J Lipid Res. 2017 May; 58(5)824-836. doi: 10.1194/jlr.R075481.

PMID:
    28246336
    [PubMed - in process]
Related citations


Automated selective disruption of slow wave sleep.
Ooms SJ, Zempel JM, Holtzman DM, Ju YS
J Neurosci Methods. 2017 Apr 1; 28133-39. doi: 10.1016/j.jneumeth.2017.02.008.

PMID:
    28238859
    [PubMed - in process]
Related citations


Sleep in Alzheimer's Disease - Beyond Amyloid.
Holth J, Patel T, Holtzman DM
Neurobiol Sleep Circadian Rhythms. 2017 Jan; 24-14. doi: 10.1016/j.nbscr.2016.08.002.

PMID:
    28217760
    [PubMed - in process]
Related citations


Cerebrospinal fluid biomarkers of infantile congenital hydrocephalus.
Limbrick DD Jr, Baksh B, Morgan CD, Habiyaremye G, McAllister JP 2nd, Inder TE, Mercer D, Holtzman DM, Strahle J, Wallendorf MJ, Morales DM
PLoS One. 2017; 12(2)e0172353. doi: 10.1371/journal.pone.0172353.

PMID:
    28212403
    [PubMed - in process]
Related citations


APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice.
Pankiewicz JE, Baquero-Buitrago J, Sanchez S, Lopez-Contreras J, Kim J, Sullivan PM, Holtzman DM, Sadowski MJ
Mol Neurodegener. 2017 Jan 31; 12(1)12. doi: 10.1186/s13024-017-0156-1.

PMID:
    28143566
    [PubMed - in process]
Related citations


Erratum to: Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation.
Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takano T, Holtzman DM, Nedergaard M, Deane R
Mol Neurodegener. 2017 Jan 12; 12(1)3. doi: 10.1186/s13024-016-0147-7.

PMID:
    28081701
    [PubMed - in process]
Related citations


Antibody Therapeutics Targeting Aβ and Tau.
Gallardo G, Holtzman DM
Cold Spring Harb Perspect Med. 2017 Jan 6; pii: a024331. doi: 10.1101/cshperspect.a024331.

PMID:
    28062555
    [PubMed - as supplied by publisher]
Related citations


Reply.
Ju YS, Holtzman DM
Ann Neurol. 2017 Feb; 81(2)322-323. doi: 10.1002/ana.24849.

PMID:
    28019658
    [PubMed - in process]
Related citations


Glymphatic distribution of CSF-derived apoE into brain is isoform specific and suppressed during sleep deprivation.
Achariyar TM, Li B, Peng W, Verghese PB, Shi Y, McConnell E, Benraiss A, Kasper T, Song W, Takana T, Holtzman DM, Nedergaard M, Deane R
Mol Neurodegener. 2016 Dec 8; 11(1)74.

PMID:
    27931262
    [PubMed - in process]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians work collaboratively with pharmaceutical or medical device companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our faculty physicians are paid by these commercial companies to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this web site, physicians earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following earned financial interests during calendar year 2016.

Company Name: C2N Diagnostics

Royalties: > $1M

Equity: Yes

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees:

Reporting Date: May 01, 2017


Company Name: Neurophage

Royalties:

Equity: No

Consulting/Advisory Board: $10,001 - $25,000

Speaker Fees:

Reporting Date: May 01, 2017


Company Name: Denali

Royalties: $10,001 - $25,000

Equity: No

Consulting/Advisory Board: $1,000 - $10,000

Speaker Fees:

Reporting Date: May 01, 2017

Areas of Research Interest

Underlying mechanisms that lead to Alzheimer's disease.